Osteoporosis Clinical Trial
Official title:
Skeletal Health in Bariatric Surgery Patients
NCT number | NCT03331536 |
Other study ID # | IRB-300000701 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 22, 2018 |
Est. completion date | August 2, 2020 |
Verified date | August 2020 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The investigators propose a prospective cohort trial that will help to understand the impact of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in pre- and post-menopausal female bariatric patients.
Status | Completed |
Enrollment | 27 |
Est. completion date | August 2, 2020 |
Est. primary completion date | August 2, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - Adult females = 19 years scheduled to undergo bariatric surgery (Roux en Y Gastric Bypass or Gastric Sleeve Surgery) - Class II (BMI 35-39.9 kg/m2). - Class III obesity (BMI = 40 kg/m2). - Scheduled to undergo bariatric surgery with the ability to provide informed consent. Exclusion Criteria: - Patients with a history of thyroid disorders, thyroidectomy and levothyroxine use. - Patients with a history of known osteoporosis, steroid-induced osteoporosis, current or previous use of medications for osteoporosis. - Patients with a history of gastrointestinal malabsorption. - Patients with a history of renal diseases. - Patients with a history of current or previous use of corticosteroids. - Patients who have used tobacco products within a year of study enrollment. - Patients with surgically-induced menopause e.g. bilateral salpingo-oophorectomy. - Patients with a history of breast cancer, who have had or are currently on hormonal therapy or anti-hormonal therapy. |
Country | Name | City | State |
---|---|---|---|
United States | UAB Kirklin Clinic Digestive Health Center | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | American Society for Metabolic and Bariatric Surgery |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine and quantify changes in bone mineral density after bariatric surgery (Roux en Y vs. Gastric Sleeve) in pre- and post-menopausal women. | Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density, BMD (in g/cm2) of the lumbar spine (L1-L4), total hip, femoral neck, distal radius, sub-total whole body (excluding only the head), and whole body. T scores will be evaluated and Z scores will be evaluated. T-scores between +1 and -1 is considered normal or healthy, T-scores between -1 and -2.5 indicates that you have low bone mass, although not low enough to be diagnosed with osteoporosis, T-scores of -2.5 or lower indicates that you have osteoporosis. For premenopausal women under the age of 50, the Z-score is used for diagnosis. Using the criteria defined by the International Society for Clinical Densitometry: If the Z-score is -2.0 or lower, the result will be below the expected range for age. If the Z score is above -2.0, the result is will be defined as within the expected range for age. | Baseline | |
Primary | Determine and quantify changes in bone mineral density after bariatric surgery (Roux en Y vs. Gastric Sleeve) in pre- and post-menopausal women. | Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density, BMD (in g/cm2) of the lumbar spine (L1-L4), total hip, femoral neck, distal radius, sub-total whole body (excluding only the head), and whole body. T scores will be evaluated and Z scores will be evaluated. T-scores between +1 and -1 is considered normal or healthy, T-scores between -1 and -2.5 indicates that you have low bone mass, although not low enough to be diagnosed with osteoporosis, T-scores of -2.5 or lower indicates that you have osteoporosis. For premenopausal women under the age of 50, the Z-score is used for diagnosis. Using the criteria defined by the International Society for Clinical Densitometry: If the Z-score is -2.0 or lower, the result will be below the expected range for age. If the Z score is above -2.0, the result is will be defined as within the expected range for age. | Baseline to 12 months | |
Primary | Determine and quantify changes in bone mineral density after bariatric surgery (Roux en Y vs. Gastric Sleeve) in pre- and post-menopausal women. | Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density, BMD (in g/cm2) of the lumbar spine (L1-L4), total hip, femoral neck, distal radius, sub-total whole body (excluding only the head), and whole body. T scores will be evaluated and Z scores will be evaluated. T-scores between +1 and -1 is considered normal or healthy, T-scores between -1 and -2.5 indicates that you have low bone mass, although not low enough to be diagnosed with osteoporosis, T-scores of -2.5 or lower indicates that you have osteoporosis. For premenopausal women under the age of 50, the Z-score is used for diagnosis. Using the criteria defined by the International Society for Clinical Densitometry: If the Z-score is -2.0 or lower, the result will be below the expected range for age. If the Z score is above -2.0, the result is will be defined as within the expected range for age. | Baseline to 24 months | |
Primary | Fracture risk assessment in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | Assessment of fracture risk using the WHO Fracture Risk Assessment Tool (FRAX) will be used to assess the 10-year fracture risk probability (in %) | Baseline | |
Primary | Fracture risk assessment in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | Assessment of fracture risk using the WHO Fracture Risk Assessment Tool (FRAX) will be used to assess the 10-year fracture risk probability (in %) | Baseline to 12 months | |
Primary | Fracture risk assessment in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | Assessment of fracture risk using the WHO Fracture Risk Assessment Tool (FRAX) will be used to assess the 10-year fracture risk probability (in %) | Baseline to 24 months | |
Primary | TBS adjustment of FRAX scores for an enhanced fracture risk probability in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | The Trabecular Bone Score (TBS) is derived from the texture of the DXA image and has been shown to be related to fracture risk. Trabecular Bone Score (TBS) software will be used to adjust fracture risk (FRAX) scores to obtain TBS scores (in gradient risk). FRAX adjusted TBS scores (in gradient of risk) ranges from 1.1% -1.9% coefficient of variation (C.V.) | Baseline | |
Primary | TBS adjustment of FRAX scores for an enhanced fracture risk probability in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | The Trabecular Bone Score (TBS) is derived from the texture of the DXA image and has been shown to be related to fracture risk. Trabecular Bone Score (TBS) software will be used to adjust fracture risk (FRAX) scores to obtain TBS scores (in gradient risk). FRAX adjusted TBS scores (in gradient of risk) ranges from 1.1% -1.9% coefficient of variation (C.V.) | Change from baseline to 12 months | |
Primary | TBS adjustment of FRAX scores for an enhanced fracture risk probability in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | The Trabecular Bone Score (TBS) is derived from the texture of the DXA image and has been shown to be related to fracture risk. Trabecular Bone Score (TBS) software will be used to adjust fracture risk (FRAX) scores to obtain TBS scores (in gradient risk). FRAX adjusted TBS scores (in gradient of risk) ranges from 1.1% -1.9% coefficient of variation (C.V.) | Change from baseline to 24 months | |
Primary | TBS assessment of bone microstructure in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | The Trabecular Bone Score (TBS) is derived from the texture of the DXA image and has been shown to be related to bone microarchitecture. Trabecular Bone Score (TBS) software will be used to assess bone microstructure. TBS =1.2 defines degraded microarchitecture, TBS between 1.20 and 1.35 is partially degraded microarchitecture, and TBS =1.35 is considered normal. | Baseline | |
Primary | TBS assessment of bone microstructure in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | The Trabecular Bone Score (TBS) is derived from the texture of the DXA image and has been shown to be related to bone microarchitecture. Trabecular Bone Score (TBS) software will be used to assess bone microstructure. TBS =1.2 defines degraded microarchitecture, TBS between 1.20 and 1.35 is partially degraded microarchitecture, and TBS =1.35 is considered normal. | Change from baseline to 12 months | |
Primary | TBS assessment of bone microstructure in pre and post-menopausal women undergoing bariatric surgery (Roux en Y vs. Gastric Sleeve). | The Trabecular Bone Score (TBS) is derived from the texture of the DXA image and has been shown to be related to bone microarchitecture. Trabecular Bone Score (TBS) software will be used to assess bone microstructure. TBS =1.2 defines degraded microarchitecture, TBS between 1.20 and 1.35 is partially degraded microarchitecture, and TBS =1.35 is considered normal. | Change from baseline to 24 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Serum bone alkaline phosphatase (BALP in U/L) will be assayed | Baseline | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Serum bone alkaline phosphatase (BALP in U/L) will be assayed | Baseline to 6 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Serum bone alkaline phosphatase (BALP in U/L) will be assayed | Baseline to 12 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Serum bone alkaline phosphatase (BALP in U/L) will be assayed | Baseline to 24 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Osteocalcin (in ng/mL) will be assayed. | Baseline | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Osteocalcin (in ng/mL) will be assayed. | Baseline to 6 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Osteocalcin (in ng/mL) will be assayed. | Baseline to 12 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Osteocalcin (in ng/mL) will be assayed. | Baseline to 24 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Type 1 procollagen (P1NP, in mcg/L) will be assayed. | Baseline | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Type 1 procollagen (P1NP, in mcg/L) will be assayed. | Baseline to 6 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Type 1 procollagen (P1NP, in mcg/L) will be assayed. | Baseline to 12 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Type 1 procollagen (P1NP, in mcg/L) will be assayed. | Baseline to 24 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | C-terminal telopeptide (CTX, in pg/mL) will be assayed. | Baseline | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | C-terminal telopeptide (CTX, in pg/mL) will be assayed. | Baseline to 6 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | C-terminal telopeptide (CTX, in pg/mL) will be assayed. | Baseline to 12 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | C-terminal telopeptide (CTX, in pg/mL) will be assayed. | Baseline to 24 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Calcium (in mg/dL), albumin (in, g/dL) will be assayed. | Baseline | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Calcium (in mg/dL), albumin (in, g/dL) will be assayed. | Baseline to 6 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Calcium (in mg/dL), albumin (in, g/dL) will be assayed. | Baseline to 12 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Calcium (in mg/dL), albumin (in, g/dL) will be assayed. | Baseline to 24 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Parathyroid hormone (PTH, in pg/mL) will be assayed. | Baseline | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Parathyroid hormone (PTH, in pg/mL) will be assayed. | Baseline to 6 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Parathyroid hormone (PTH, in pg/mL) will be assayed. | Baseline to 12 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | Parathyroid hormone (PTH, in pg/mL) will be assayed. | Baseline to 24 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | 25-OH vitamin D (in ng/mL) will be assayed. | Baseline | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | 25-OH vitamin D (in ng/mL) will be assayed. | Baseline to 6 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | 25-OH vitamin D (in ng/mL) will be assayed. | Baseline to 12 months | |
Secondary | Determine and quantify changes in biochemical markers of bone metabolism and calcium homeostasis. | 25-OH vitamin D (in ng/mL) will be assayed. | Baseline to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Completed |
NCT03822078 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
|
Phase 1 | |
Recruiting |
NCT05845021 -
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04736693 -
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
|
||
Not yet recruiting |
NCT06431867 -
Primary Care Management of Osteoporosis in Older Women
|
||
Completed |
NCT02922478 -
Role of Comorbidities in Chronic Heart Failure Study
|
||
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Active, not recruiting |
NCT02617303 -
Prevention of Falls and Its Consequences in Elderly People
|
N/A | |
Completed |
NCT02566655 -
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
|
Phase 1 | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Completed |
NCT03420716 -
Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women
|
N/A | |
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Completed |
NCT02003716 -
DeFRA Questionnaire as an Anamnestic Form
|
N/A | |
Not yet recruiting |
NCT01854086 -
Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
|
N/A | |
Unknown status |
NCT01913834 -
Nasally and sc Administered Teriparatide in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01694784 -
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
|
N/A | |
Completed |
NCT01757340 -
Calorie Restriction With Leucine Supplementation
|
N/A |